ACHEAV

Welcome to the Brand page for “ACHEAV”, which is offered here for Pharmaceutical preparations for treating von willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant dna technology for the treatment of hemophilia, pharmaceutical preparations derived from recombinant dna technology for the treatment of hemophilia; blood products for the treatment of hemophilia, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, cells for medical or clinical use; cell cultures for medical purposes, living cells for medical use; cell cultures for medical purposes, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; pharmaceutical preparations, antibody for the treatment of acute respiratory distress syndrome, ards; pharmaceutical preparations, antibody for the treatment of idiopathic pulmonary fibrosis, ipf and interstitial lung diseases, ild; pharmaceutical preparations, antibody for the treatment of hereditary angioedema, hae; and not for smoking cessation treatment;.

Its status is currently believed to be active. Its class is unavailable. “ACHEAV” is believed to be currently owned by “CSL BEHRING GMBH”.